miR-126 Suppresses the Proliferation of Cervical Cancer Cells and Alters Cell Sensitivity to the Chemotherapeutic Drug Bleomycin

  • Yu, Qing (Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University) ;
  • Liu, Shan-Ling (Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University) ;
  • Wang, He (Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University) ;
  • Shi, Gang (Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University) ;
  • Yang, Pei (Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University) ;
  • Chen, Xin-Lian (Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University)
  • Published : 2013.11.30


In cervical cancer, one of the most common malignant tumors in women worldwide, miR-126 has been reported to exhibit decreased expression. However, its role in cervical cancer cell proliferation and drug sensitivity has remained relatively unexplored. Here, we compared the expression of miR-126 in cervical cancer tissues (n = 20) with that in normal cervical tissue (n = 20) using quantitative RT-PCR. The viability of Siha cervical cancer cells was further measured by MTT assay after transfection with miR-126 mimic (Siha-miR-126 mimic) or microRNA mimic negative control (Siha-miR mimic NC) and after treatment with various concentrations of bleomycin (BLM). IC50s were calculated, and the survival rates (SRs) of Siha cells were calculated. miR-126 expression in cervical cancer tissue was significantly decreased compared with that in normal cervical tissue (P < 0.01). The relative SRs of Siha-miR-126 mimic cells were also significantly decreased compared with those of Siha-miR mimic NC cells at 24-96 h after transfection. The IC50 of BLM in Siha-miR-126 mimic cells ($50.3{\pm}2.02{\mu}g/mL$) was decreased compared with that in Siha-miR mimic NC cells ($70.5{\pm}4.33{\mu}g/mL$) at 48 h after transfection (P < 0.05). Finally, the SRs of Siha-miR-126 mimic cells were significantly lower than those of SihamiR mimic NC cells after cultured in medium containing 40 ${\mu}g/mL$ BLM for 24-96 h (P < 0.05). These results suggest that miR-126 is expressed at low levels in cervical cancer. Upregulation of miR-126 inhibited cervical cancer cell proliferation and enhanced the sensitivity to BLM. Thus, miR-126 may represent a novel approach to cervical cancer treatment.


miR-126;cervical cancer;bleomycin;drug sensitivity


  1. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
  2. Feng R, Chen X, Yu Y, et al (2010). miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett, 298, 50-63.
  3. Hamada S, Satoh K, Fujibuchi W, et al (2011). MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res, 10, 3-10.
  4. Harris TA, Yamakuchi M, Ferlito M, et al (2008). MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A, 105, 1516-21.
  5. Hong L, Piao Y, Han Y, et al (2005). Zinc ribbon domain-containing 1(ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther, 4, 1936-42.
  6. Hou J, Lin L, Zhou W, et al (2011). Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell, 19, 232-43.
  7. Hu X, Schwarz JK, Lewis JS Jr, et al (2010). A microRNA expression signature for cervical cancer prognosis. Cancer Res, 70, 1441-8.
  8. Kuhnert F, Mancuso MR, Hampton J, et al (2008). Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development, 135, 3989-93.
  9. Li JH, Xiao X, Zhang YN, et al (2011). MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol, 120, 145-51.
  10. Musiyenko A, Bitko V, Barik S (2008). Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. Mol Med (Berl), 86, 313-22.
  11. Oglesby IK, Bray IM, Chotirmall SH, et al (2010). miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol, 184, 1702-9.
  12. van Solingen C, de Boerl HC, Bijkerk R, et al (2011). MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-11/Lin2 progenitor cells in ischaemia. Cardiovasc Res, 92, 449-55.
  13. Wang X, Tang S, Le SY, et al (2008). Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 3, e2557.
  14. Wang S, Aurora AB, Johnson BA, et al (2008b). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell, 15, 261-71.
  15. Yang Z, Chen S, Luan X, et al (2009). MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life, 61, 1075-82.
  16. Zampetaki A, Kiechl S, Drozdov I, et al (2010). Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res, 107, 810-7.
  17. Zhu N, Zhang D, Xie H, et al (2011). Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem, 351, 157-64.
  18. Zhu X, Li H, Long L, et al (2012). miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin, 44, 519-26.

Cited by

  1. MiRNA-15a Mediates Cell Cycle Arrest and Potentiates Apoptosis in Breast Cancer Cells by Targeting Synuclein-γ vol.15, pp.16, 2014,
  2. Characterization of the MicroRNA Expression Profile of Cervical Squamous Cell Carcinoma Metastases vol.15, pp.4, 2014,
  3. Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer vol.9, pp.1, 2014,
  4. Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer vol.2, pp.2296-861X, 2015,
  5. Notch1 ligand signaling pathway activated in cervical cancer: poor prognosis with high-level JAG1/Notch1 vol.292, pp.4, 2015,
  6. RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren’s disease vol.8, pp.1, 2015,
  7. Methylation of miRNA genes and oncogenesis vol.80, pp.2, 2015,
  8. A comparison of microRNA expression profiles from splenic hemangiosarcoma, splenic nodular hyperplasia, and normal spleens of dogs vol.12, pp.1, 2016,
  9. MicroRNA-126 is downregulated in thyroid cancer cells, and regulates proliferation, migration and invasion by targeting CXCR4 vol.14, pp.1, 2016,
  10. MicroRNA-126 Overexpression Inhibits Proliferation and Invasion in Osteosarcoma Cells vol.15, pp.5, 2016,
  11. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes vol.37, pp.12, 2016,
  12. Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton’s Jelly Mesenchymal Stem Cell Conditioned Medium vol.13, pp.6, 2017,
  13. A systematic study on dysregulated microRNAs in cervical cancer development vol.138, pp.6, 2015,
  14. Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia vol.8, pp.1, 2018,